Activation of heteromeric G protein-gated inward rectifier K+ channels overexpressed by adenovirus gene transfer inhibits the excitability of hippocampal neurons by Ehrengruber, Markus U. et al.
Proc. Natl. Acad. Sci. USA
Vol. 94, pp. 7070–7075, June 1997
Physiology
Activation of heteromeric G protein-gated inward rectifier K1
channels overexpressed by adenovirus gene transfer inhibits
the excitability of hippocampal neurons
MARKUS U. EHRENGRUBER, CRAIG A. DOUPNIK, YOUFENG XU, JUSTINE GARVEY, MARK C. JASEK,
HENRY A. LESTER, AND NORMAN DAVIDSON*
Division of Biology, 156–29, California Institute of Technology, Pasadena, CA 91125
Contributed by Norman Davidson, April 16, 1997
ABSTRACT G protein-gated inward rectifier K1 channel
subunits 1–4 (GIRK1–4) have been cloned from neuronal and
atrial tissue and function as heterotetramers. To examine the
inhibition of neuronal excitation by GIRKs, we overexpressed
GIRKs in cultured hippocampal neurons from 18 day rat
embryos, which normally lack or show low amounts of GIRK
protein and currents. Adenoviral recombinants containing the
cDNAs for GIRK1, GIRK2, GIRK4, and the serotonin 1A
receptor were constructed. Typical GIRK currents could be
activated by endogenous GABAB, serotonin 5-HT1A, and aden-
osine A1 receptors in neurons coinfected with GIRK112 or
GIRK114. Under current clamp, GIRK activation increased
the cell membrane conductance by 1- to 2-fold, hyperpolarized
the cell by 11–14 mV, and inhibited action potential firing by
increasing the threshold current for firing by 2- to 3-fold.
These effects were not found in non- and mock-infected
neurons, and were similar to the effects of muscarinic stim-
ulation of native GIRK currents in atrial myocytes. Two
inhibitory effects of GIRK activation, hyperpolarization and
diminution of depolarizing pulses, were simulated from the
experimental data. These inhibitory effects are physiologi-
cally important in the voltage range between the resting
membrane potential and the potential where voltage-gated
Na1 and K1 currents are activated; that is where GIRK
currents are outward.
G protein-gated inward rectifier K1 channels (GIRKs) ex-
pressed in neuronal, atrial, and other cell types are formed by
subunits encoded by a five-membered gene subfamily (Kir 3.0),
and are activated by neuromodulators acting on G protein-
coupled receptors (1, 2). Although GIRKs are inward rectifi-
ers, their usual physiological role is to permit an outward K1
current near resting membrane potentials (EM; ref. 3). This
hyperpolarizing K1 current through activated GIRKs presum-
ably functions to decrease cellular excitability, detected, e.g., as
slowing of the heart beat (vagusstoff response, ref. 4) and
reduction of spike (i.e., action potential) train frequencies in
neurons (reviewed, e.g., in refs. 5 and 6).
GIRKs normally function as heterotetrameric channels of
two or more subunit isoforms (2, 7–10). The isoforms
GIRK1–3 and, to a lesser extent, GIRK4 are expressed in
CA1–CA3 pyramidal and dentate gyrus granule cells of the rat
hippocampus (10, 11), where GIRK-type K1 currents have
previously been described (e.g., refs. 12–14). To analyze the
role of cloned GIRKs in hippocampal excitation, we have
developed a recombinant adenovirus system for coexpressing
several GIRKs and a G protein-coupled receptor in neurons at
a high per cell efficiency. Here we report a quantitative study
of the inhibition of spike train initiation in cultured rat
hippocampal neurons in which GIRK1 and GIRK2 have been
overexpressed and activated by endogenous G protein-coupled
receptors.
MATERIALS AND METHODS
Cell Culture and Reagents. Cultures of 18 day embryonic
(E18) rat hippocampal neurons and 4–6 day (d) postnatal rat
atrial and ventricular myocytes, pancreatic bTC3 cells (gift
from S. Efrat, Albert Einstein College of Medicine), and
Xenopus oocytes were prepared as described (8, 15, 16).
Chinese hamster ovary (CHO) cells (American Type Culture
Collection) were maintained at 5% CO2y95% air in Ham’s
F-12 medium (Irvine Scientific) containing 10% fetal bovine
serum (Irvine Scientific). Total RNA was extracted using
Rneasy (Qiagen, Chatsworth, CA). Muscarinic M2 receptor
cRNA (17) was synthesized in vitro from HindIII-linearized
plasmid (gift from E. G. Peralta, Harvard University Medical
School) using Message machine (Ambion, Austin, TX).
Spermine, (6)-baclofen, and serotonin (5-HT) were from
Sigma; 2-chloro-N6-cylcopentyladenosine (CCPA) and (6)-8-
hydroxy-dipropylaminotetralin (8-OH-DPAT) from Research
Biochemicals; [D-Ala2-Met5]enkephalin was from Calbio-
chem.
Adenoviral Constructs. By using standard techniques (18),
adenoviral recombinants were constructed with the following
cDNA inserts under the control of a cytomegalovirus pro-
moter: GIRK1 (ref. 19; AdGIRK1), GIRK2 (ref. 20, gift from
D. E. Clapham, McMaster University; AdGIRK2), GIRK4
(ref. 21, gift from J. P. Adelman, University of Oregon;
AdGIRK4), and Shaker H4 K1 channel (22). GIRK1, GIRK2,
and GIRK4 were inserted into adenovirus AdPacI (gift from
F. L. Graham, McMaster University); Shaker H4 was inserted
into AdD309 (gift from A. J. Berk, University of California,
Los Angeles). The 5-HT1A receptor cDNA (23) was ligated
into AdRR5 (ref. 24, gift from R. D. Gerard, University of
Texas) to obtain Ad5HT1AR. Adenovirus containing Esche-
richia coli LacZ cDNA (AdLacZ) was a gift from A. J. Berk.
We frequently tested functionality of cDNA inserts, such as
GIRK1 plus GIRK2 cloned into the pAC adenovirus transfer
plasmid (18), by Lipofectamine cotransfection prior to making
the recombinant viruses. Viruses were propagated in HEK293
cells (American Type Culture Collection) maintained at 5%
CO2y95% air in Dulbecco’s modified Eagle’s medium (Irvine
Scientific), supplemented with 10% fetal bovine serum. For
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infection, cells plated in 35 mm Petri dishes (Corning) were
incubated for 2 hr in 750 ml of conditioned medium containing
virus with gentle mixing every 15 min, then washed twice and
cultured for 1–7 d. b-galactosidase detection was as described
(25).
Western Blots. GIRK1 and GIRK2 proteins were detected
by Western blots using affinity-purified GIRK-specific anti-
bodies. A previously described rabbit anti-GIRK1 antibody
was used (15, 26). For GIRK2, a guinea pig anti-GIRK2
antibody was produced against a glutathione S-transferase
fusion protein carrying the GIRK2-unique N terminal aa 1–24.
It displayed high specificity as determined by Western blot and
immunocytochemistry in transfected COS cells (data not
shown). Dissected adult rat hippocampus and cultured E18
hippocampal neurons were solubilized in 62.5 mM TriszHCl
(pH 6.8), 1% SDS, 10% (volyvol) glycerol, 100 mgyml phenyl-
methylsulfonyl f luoride (Sigma), 2 mgyml leupeptin (Sigma), 1
mgyml pepstatin A (Sigma), and 1 mgyml aprotinin (Boehr-
inger Mannheim). Lysate proteins were separated by 10%
SDSyPAGE and transferred to Immobilon-P membranes (Mil-
lipore). Primary antibody binding at 0.1 (GIRK1) and 1 mgyml
(GIRK2) was carried out in phosphate-buffered saline con-
taining 0.1% Tween-20 and 5% dried milk (blocking solution);
the horseradish peroxidase-conjugated secondary antibodies
anti-rabbit IgG (Boehringer Mannheim) and anti-guinea pig
IgG (Jackson ImmunoResearch) were used at 40 ngyml in
blocking solution. Immunodetection was by enhanced chemi-
luminescence (Amersham). As a control for the specificity of
immunoreactive bands, primary antibody preabsorption with
the respective GIRK1 or GIRK2 immunogen was performed
by overnight incubation at 4°C.
Electrophysiology. Whole-cell patch-clamp recording was
performed using borosilicate glass capillaries (Sutter Instru-
ments, Novato, CA) pulled to a tip resistance of 2–7 MV and
coated with Sylgard. Signals were recorded with an Axopatch
1D amplifier (Axon Instruments, Foster City, CA) interfaced
to a 386 personal computer through a Digidata 1200 (Axon
Instruments). Current and voltage commands, data acquisi-
tion, and analysis were performed using PCLAMP 6.0. Record-
ings in myocytes, CHO, and bTC3 cells were performed as
described (23). For neurons, the bath solution contained 120
mM NaCl, 2.5 mM KCl, 5 mM Hepes, 2 mM CaCl2, 1 mM
MgCl2, 10 mM glucose (pH 7.3 with NaOH, '260 mOsm); the
pipette solution contained 5 mM KCl, 125 mM K gluconate,
5 mM Hepes, 5 mM Na2 phosphocreatine, 1.1 mM EGTA, 0.1
mM CaCl2, 2 mM MgCl2, 4 mM MgATP, 0.3 mM Na2GTP (pH
7.2 with KOH, '250 mOsm). For recordings at 25 mM [K1]o,
NaCl was replaced by KCl. At low [K1]o, the calculated
junction potentials (using Jpcalc 2.0 and ion mobilities given in
refs. 27 and 28) were 114 mV (neurons) and 14 mV (atrial
cells). In the data below, measured EM are reported without a
junction potential correction. Shaker currents were activated in
5.4 mM [K1]o by depolarization pulses to 250 to 140 mV
(after a 20 msec hyperpolarizing pulse at 2100 mV). GIRK
currents were assessed by applying 2-sec voltage ramp proto-
cols from 2140 to 120 mV before and during agonist perfu-
sion. Holding EM was 270 mV; signals were sampled at 0.5–2
kHz, and series resistance compensation was not employed.
GIRK currents in Xenopus oocytes were assayed as described
(8). All recordings were at room temperature. The simulations
in Fig. 5 were performed using Axon Engineer Pro (Axon
Instruments).
RESULTS AND DISCUSSION
Test of Adenoviral Gene Expression. In preparation for
adenoviral GIRK expression, we examined the virus titer
needed for high infection levels in E18 hippocampal cell
cultures using AdLacZ expressing the reporter gene b-galac-
tosidase. A titer of $5 3 107 plaque-forming unitsyml resulted
in b-galactosidase staining of .99% of the neurons; lower
titers gave incomplete staining ('30% at 106 and '80% at 107
plaque-forming unitsyml). Based on these results, we used
titers of '108 plaque-forming unitsyml per virus to achieve
complete infection in our transfection experiments. Before
attempting to express heteromeric GIRKs, we first tested the
adenoviral expression of homomeric Shaker K1 channels.
Atrial and ventricular myocytes, and bTC3 and CHO cells
infected with the Shaker adenovirus expressed new large
transient K1 currents as soon as 1 d postinfection (120 6 10
pAypF in myocytes, n 5 3, mean 6 SEM of peak currents at
130 mV), persisting for the longest time span tested (5 d;
250 6 120 pAypF, n 5 4). Taken together, these data suggest
that adenovirus is useful for expression of K1 channels in
various cell types, including hippocampal neurons.
As an initial test of adenovirus containing GIRK1 cDNA, we
infected pancreatic bTC3 cells, which have been reported to be
suitable for functional GIRK1 expression (29). However, we
could not detect any GIRK currents in these cells 1–2 d
postinfection. By contrast, Xenopus oocytes injected with 0.2
ng of muscarinic M2 receptor cRNA together with 100 ng total
RNA from AdGIRK1-infected bTC3 cells, but not with M2
receptor plus total RNA from noninfected cells, did express
acetylcholine (ACh)-activated GIRK currents (520 6 70 pA at
2120 mV and 98 mM [K1]o, 3 d after injection, n 5 13). This
result shows that AdGIRK1 produces intact GIRK1 mRNA
and expresses protein that coassembles with GIRK5 in Xeno-
pus oocytes (2) to form functional GIRKs. In our experiments
on bTC3 cells, however, an unknown mechanism, such as
failure to express GIRK2 andyor GIRK4 (30), interfered with
functional GIRK1 expression.
We then coinfected CHO cells with Ad5HT1AR plus either
AdGIRK112 or AdGIRK114. These cells showed large ag-
onist-activated GIRK currents, whereas no GIRK currents
could be detected in cells transfected with receptor plus
GIRK1 alone (data not shown). The 5-HT-activated GIRK
currents for Ad5HT1AR plus AdGIRK114-coinfected cells 2 d
postinfection were 250 6 28 pAypF (at 25 mM [K1]o and
2120 mV, n 5 3). These results demonstrate that a single cell
can be infected by at least three different adenoviruses, when
useful for the functional expression of heteromeric channels.
Overall, these data confirm that GIRKs function in mamma-
lian cells as heteromers (7, 10).
Expression of GIRK1 and GIRK2 Proteins in Hippocampal
Neurons. Fig. 1a shows Western blots of lysate from (i) adult
hippocampus, (ii) E18 hippocampal neurons cultured for 4 d,
and (iii) 4 d-cultured hippocampal neurons 3 d after coinfec-
tion with AdGIRK112. A single 60-kDa band, consistent with
glycosylated GIRK1 protein (7), was detected in adult hip-
pocampus but not in 4 d-cultured E18 hippocampal neurons.
Coinfection with AdGIRK112 produced an '30-fold increase
in GIRK1 immunoreactive protein compared with adult hip-
pocampus. In addition to the putative 60-kDa glycosylated
GIRK1 band, a significant 52–56-kDa doublet band was ob-
served, consistent with unglycosylated GIRK1 (7). Bands with
.100 kDa mobility were also present. Since all bands were
blocked by immunogenic peptide preabsorption (data not
shown), the upper bands are thought to be aggregates, includ-
ing overexpressed GIRK1 protein. Densitometric comparison
of the 60-kDa bands indicates a more modest, 8-fold increase
in glycosylated GIRK1 by adenoviral overexpression.
GIRK2 protein was detected in adult hippocampus as an
'49 kDa protein that was not found in 4 d-cultured E18
hippocampal neurons. Coinfection with AdGIRK112 pro-
duced an '60-fold increase in GIRK2 immunoreactive prod-
ucts compared with the adult hippocampus (Fig. 1a). An '46
kDa significant band was present in addition to the higher
molecular weight bands as observed for GIRK1. All bands
were blocked by preabsorption with the immunogenic fu-
sion protein (data not shown). The higher molecular weight
Physiology: Ehrengruber et al. Proc. Natl. Acad. Sci. USA 94 (1997) 7071
of the GIRK2 protein in adult hippocampus (49 kDa) vs. the
AdGIRK2-expressed 46 kDa protein may indicate the expres-
sion of a longer, alternatively spliced GIRK2 isoform in adult
hippocampus (31) or may be due to unknown posttranslational
modifications. Quantitative comparison of these bands indi-
cates an 8-fold overexpression of GIRK2 protein, equivalent to
the GIRK1 data.
Our finding that in embryonic neurons cultured for 4 d little
or no GIRK1 and GIRK2 protein levels were detectable (3 and
6% of adult hippocampus, respectively) is supported by pre-
vious studies reporting that GIRK expression is postnatal (32).
To examine whether developmental GIRK expression in vivo
can be mimicked in vitro, we analyzed cells that had been
cultured for longer periods. As shown in Fig. 1b, we could
measure low amounts of GIRK1 and GIRK2 proteins in E18
neurons after 14 d and increased amounts after 21 d in culture
(4 and 11% of adult for GIRK1, respectively, and 28 and 29%
for GIRK2). These results indicate that expression of GIRKs
occurs in long-term cultures of E18 hippocampal neurons;
however, expression levels are lower than in vivo.
Expression of GIRK Currents. We could not detect any
GIRK currents activated by the GABAB receptor agonist
baclofen or by 5-HT in uninfected E18 hippocampal neurons
#11 d in culture. In older cell cultures ($13 d), however, we
found small baclofen-activated GIRK currents (21.9 6 0.4
pAypF, n 5 6, at 2140 mV and 2.5 mM [K1]o). This
time-dependent expression of GIRK currents parallels the
appearance of GIRK proteins in uninfected E18 hippocampal
cell cultures (see above). In contrast to uninfected cells, large
baclofen-activated GIRK currents sensitive to 0.5 mM Ba21
were apparent in hippocampal neurons that had been coin-
fected with either AdGIRK112 or AdGIRK114 (Fig. 2). At
2 d postinfection, 25 mM [K1]o, and 2120 mV, these GIRK
currents were 276 6 12 pAypF (n 5 5) and 255 6 17 pAypF
(n 5 4), respectively, comparable to 5-HT-activated GIRK
currents found in infected CHO cells (above), and 3.7–5 times
larger than the endogenous ACh-activated GIRK currents in
atrial cells (215 6 2 pAypF, n 5 23). These results, together
with the Western blot data, demonstrate that GIRK overex-
pression is achievable using adenoviral delivery, thus making
it practical to study GIRK function in cultured hippocampal
neurons.
To examine GIRK function under more physiological con-
ditions, measurements were performed at physiological [K1]o,
2.5 mM for neurons and 5.4 mM for atrial cells. In
AdGIRK112-coinfected neurons, both baclofen (50 mM) and
5-HT (30 mM) induced prominent inward currents (Fig. 3
Upper Left), as did ACh in atrial myocytes (Fig. 3 Lower Left).
Positive to the reversal potentials of 289.9 6 0.8 mV for
neurons (n 5 20; EK 5 '299 mV) and 279.0 6 0.7 mV for
myocytes (n 5 17; EK 5 282 mV), relatively large outward K1
FIG. 2. Adenovirus-mediated expression of GIRK currents in
hippocampal neurons. Cells cultured for 5 d were coinfected with
AdGIRK112 or AdGIRK114 and analyzed 2 d postinfection in 25
mM [K1]o and 250 nM tetrodotoxin. Currents in the presence (b) and
absence (a) of 100 mM baclofen; 0.5 mM Ba21 blocked basal and
baclofen-activated GIRK currents (c).
FIG. 3. Cellular responses to GIRK activation at physiological
[K1]o. (Left) Currents activated by 30 mM 5-HT and 50 mM baclofen
in AdGIRK112-coinfected (4 d postinfection, thick lines) and unin-
fected (fine line, 5-HT only) hippocampal neurons 11 d in culture
(Upper), and by 5 mM ACh in an atrial cell (Lower). (Right) EM changes
caused by application of 50 mM baclofen and 5 mM ACh (bars); resting
EM were 268 (neuron) and 224 mV (myocyte). Similar responses
were observed to 8-OH-DPAT in neurons. The mean resting EM of 15
atrial cells was 235.8 6 3.8 mV.
FIG. 1. Expression of GIRK proteins in cultured rat E18 hip-
pocampal neurons. (a) Overexpression of GIRK1 and GIRK2 proteins
in cells coinfected with AdGIRK112. Total cellular protein was
loaded (50 mg per lane): adult hippocampus (lane 1); 4 d-cultured
neurons (lane 2); 4 d-cultured AdGIRK112-coinfected neurons, 3 d
postinfection (lane 3). Left and right blots were probed with affinity-
purified anti-GIRK1 and -GIRK2 antibodies, respectively. Protein
samples were separated by SDSyPAGE with prestained molecular
weight markers (Amersham) in neighboring lanes. The molecular
weights of the marker proteins are indicated on the left with dotted
lines across the gels. (b) Time-dependent expression of GIRK1 (Upper)
and GIRK2 protein (Lower) in vitro. Total cellular protein of E18
neurons cultured for 4, 14, and 21 d, and of adult hippocampus was
used (100 mg per lane) and probed with affinity-purified anti-GIRK1
and -GIRK2 antibodies, respectively.
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currents were apparent. For neurons, the agonist-activated
outward GIRK currents at 240 mV (I240 mV) were 21 6 1%
(n 5 12, baclofen) and 26 6 2% (n 5 11, 5-HT) of the inward
currents at 2140 mV, indicating conductance ratios of 4–5 3
1023. The important point, nevertheless, is that in the range
between the resting EM and '240 mV, where currents due to
voltage-gated channels are negligible, there is a significant
agonist-activated outward K1 current.
In AdGIRK112-coinfected neurons, the 50 mM baclofen-
activated I240 mV was $5 times larger than in AdLacZ- and
noninfected neurons; 30 mM 5-HT caused an even larger
response (P 5 0.02, t test; Table 1). Similar results were
obtained using the 5-HT1A receptor-specific agonist 8-OH-
DPAT (30 mM; Table 1), suggesting that the 5-HT response is
exerted via 5-HT1A receptors. Overexpression of these recep-
tors by coinfection with Ad5HT1AR did not increase the
agonist-activated I240 mV (5.1 6 1.7 pAypF, n 5 7 vs. 3.5 6 1.1
pAypF, n 5 6, for Ad5HT1AR-coinfected neurons), indicating
that GIRK channel activation by endogenous 5-HT1A recep-
tors was maximal.
The intracellular polyamines spermine and spermidine are
important for the rectification of inward rectifier K1 channels
(33–35). To test whether the observed ligand-activated I240 mV
was due (at least partially) to loss of intracellular polyamines
during whole-cell recording, we tested whether the addition of
a natural [spermine]i (0.1 mM; ref. 36) to the pipette solution
altered I240 mV. Both 5-HT- and baclofen-activated I240 mV in
neurons and ACh-evoked I240 mV in atrial cells were un-
changed by the addition of spermine (data not shown), sug-
gesting that the outward I240 mV is not due to loss of internal
blocking molecules, but instead is a result of the rectification
properties of overexpressed GIRKs under physiological con-
ditions (i.e., [K1]o, EM).
GIRK Activation and Cellular Excitability. Under current
clamp with zero-injected current, AdGIRK112-coinfected
hippocampal neurons and atrial myocytes were hyperpolarized
10–20 mV by agonist addition (Fig. 3 Right; Table 1). Fur-
thermore, the cell membrane conductance (gCell) of the neu-
rons (Table 2) and myocytes (1.4 6 0.4 nS, n 5 10), as
measured by the voltage shift due to injection of a hyperpo-
larizing current pulse, increased by 90–170% (Table 1). In
GIRK-overexpressing neurons, application of baclofen and
5-HT hyperpolarized EM by 11–14 mV and increased gCell by
1- to 2-fold, whereas AdLacZ- and noninfected cells showed
significantly lower changes (0–4 mV and 0- to 0.2-fold, re-
spectively; Table 3). 8-OH-DPAT similarly hyperpolarized EM
and increased gCell in GIRK-overexpressing cells (Table 1) but
not in AdLacZ-infected cells (DEM 5 21.0 6 0.6 mV, n 5 4,
DgCell 5 0.3 6 0.3 nS, n 5 4). AdGIRK112-coinfected neurons
showed about the same resting EM and gCell as AdLacZ- and
noninfected cells (Table 2), suggesting that basal GIRK activ-
ity does not affect resting EM.
In rat E18 hippocampal cell cultures, the majority of neurons
are pyramidal; however, GABAergic interneurons can com-
prise up to 6–36% of the cells (37, 38). Adenosine A1 receptors
coupling to GIRKs are expressed in pyramidal cells but not
interneurons (14, 37). To explore the nature of our GIRK-
overexpressing neurons, we examined whether CCPA, an
adenosine A1 receptor-selective agonist, caused excitability
changes. We also tested whether such changes were induced by
[D-Ala2-Met5]enkephalin, an agonist known to cause mem-
brane hyperpolarization in interneurons but not pyramidal
cells (39). Similarly to GABAB and 5-HT1A receptor agonists,
CCPA caused membrane hyperpolarization and increased gCell
(Table 1), whereas 10 mM [D-Ala2-Met5]enkephalin was with-
out effect (three cells tested, data not shown). These results
indicate that the majority of the hippocampal cells used in our
study were pyramidal neurons.
The consequences of GIRK-mediated changes in the cell
electrical properties are illustrated in Fig. 4. Baclofen sup-
pressed spike train firing in GIRK-overexpressing hippocam-
pal neurons in records that resembled ACh inhibition of firing
atrial myocytes (Fig. 4a). In Fig. 4b, current pulses were
injected into GIRK-overexpressing neurons in steps of 16 or 20
pA, both in the presence and absence of baclofen or 5-HT.
Without agonist, the EM plateaued in 3–5-mV steps over a time
period of '50 msec until it reached '240 mV, at which point
a slow depolarization occurred and then an action potential
was fired. Larger current injections gave rise to spike trains.
With agonist, the depolarizing steps resulting from equivalent
current injections were significantly reduced. The ITh was
increased from '60 pA to '180 pA by 5-HT for the particular
neuron shown in the top of Fig. 4b. Fig. 4b (Inset) shows that
the slope of the spike frequency vs. current relationship is
similar in the presence and absence of 5-HT for that cell.
Overall, agonist addition did not change this slope in GIRK-
overexpressing neurons (0.22 6 0.02 HzypA, n 5 46 vs. 0.20 6
0.02 HzypA, n 5 25, and 0.24 6 0.03 HzypA, n 5 15 for
baclofen and 5-HT, respectively), indicating that GIRK chan-
nels do not further influence neuronal firing once ITh has been
reached.
To measure the effect of GIRK activation on hippocampal
action potential firing, we estimated ITh both in the presence
Table 1. Comparison of agonist-induced changes in atrial
myocytes and AdGIRK112-infected hippocampal neurons
Agonist DI240 mV, pAypF DEM, mV DgCell, nS
Myocytes
ACh 1.8 6 0.2 (18) 218.9 6 3.8 (14) 1.2 6 0.5 (9)
Neurons
Baclofen 2.0 6 0.3 (12) 211.0 6 1.0 (30) 2.8 6 0.4 (30)
5-HT 4.9 6 1.1 (11) 214.4 6 1.9 (20) 4.1 6 0.5 (19)
8-OH-DPAT 1.4 6 0.1 (2) 210.9 6 2.8 (8) 4.8 6 1.9 (7)
CCPA ND 211.0 6 2.3 (7) 3.9 61.2 (7)
Means 6 SEM (n) of changes caused by 5 mM ACh at 5.4 mM [K1]o
in myocytes, and by 50 mM baclofen, 30 mM 5-HT or 8-OH-DPAT, and
3 mM CCPA at 2.5 mM [K1]o in neurons (cultured for 9–27 d, assayed
3–7 d postinfection). ND, not determined.
Table 2. Properties of unstimulated infected hippocampal neurons
Infection EM, mV gCell, nS ITh, pA
AdGIRK112 263.0 6 1.0 (65) 2.4 6 0.2 (66) 25 6 7 (46)
AdLacZ 260.4 6 0.9 (26) 1.7 6 0.2 (26) 37 6 10 (18)
Uninfected 262.0 6 1.2 (27) 2.4 6 0.3 (27) 41 6 11 (17)
Means 6 SEM (n) of neurons cultured for 9–27 d and assayed 3–7
d postinfection. ITh, the threshold current for action potential firing,
was determined as described in Fig. 4b (Inset).
Table 3. Agonist-induced excitability changes of infected hippocampal neurons
Infection
50 mM baclofen-induced changes 30 mM 5-HT-induced changes
DEM, mV DgCell, nS DITh, pA DEM, mV DgCell, nS DITh, pA
AdGIRK112 211.0 6 1.0 (30) 2.8 6 0.4 (30) 68 6 18 (25) 214.4 6 1.9 (20) 4.1 6 0.5 (19) 60 6 14 (13)
AdLacZ 23.5 6 0.7* (18) 0.3 6 0.1* (18) 23 6 6* (11) 21.6 6 2.3* (7) 0.2 6 0.2* (7) 214 6 11* (5)
Uninfected 23.0 6 0.6* (21) 0.5 6 0.2* (18) 4 6 16* (12) 20.1 6 1.2* (5) 0.0 6 0.2* (5) 220 6 29* (3)
Means 6 SEM (n) of cells cultured for 9–27 d and assayed 3–7 d postinfection. p, Significant differences (P , 0.05, t test) between this value
and the corresponding value from AdGIRK112-coinfected cells.
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and absence of agonist as described in Fig. 4b (Inset). In the
absence of agonist, ITh was similar for all neurons (Table 2).
Addition of baclofen and 5-HT increased ITh by 2- to 3-fold in
GIRK-overexpressing neurons, but not in AdLacZ- and non-
infected neurons (Table 3). 8-OH-DPAT (30 mM) and CCPA
(3 mM) had a similar effect on ITh in GIRK-overexpressing
neurons (1.4- and 2.5-fold increase, respectively). Taken to-
gether, our data provide a quantitative demonstration of how
GIRK activation inhibits neuronal action potential firing.
GIRK Function Modeling. Our results on the effect of the
GIRK conductance (gGIRK) on cell membrane properties were
further analyzed by the equivalent circuit shown in Fig. 5
(Upper Left). For the model cell, we assumed a membrane
capacitance of 50 pF in accordance with the average value for
our cultured hippocampal neurons. For simplicity, the cell
geometry was spherical and isopotential. Introduced into the
model was gGIRK described by an empirically derived Boltz-
mann relation: IGIRK(V) 5 gMax(EM 2 EK)y[1 1 exp(0.026(EM 2
E1/2))], where the maximal gGIRK (gMax) was then set at 25 nS
and the membrane potential for half conductance (E1/2) at 295
mV. The resulting GIRK current–voltage relation is shown in
Fig. 5 (Upper Right) and closely reproduces the experimental
curves from AdGIRK112-coinfected neurons (compare with
Fig. 3). EM changes in response to current injections are shown
for the model cell in the absence and presence of gGIRK (Fig.
5, Lower). Note that introducing gGIRK causes a substantial
steady hyperpolarization ('30 mV) and reduces the depolar-
ization in response to current injection. Thus, the qualitative
explanation of decreased excitability observed in GIRK-
expressing cells is that GIRK activation produces both a
hyperpolarization and an increased conductance.
Concluding Remarks. Because of the high GIRK expression
level achieved by adenovirus-mediated gene expression, it has
been possible in this study to measure the important outward
GIRK current between the resting EM and the membrane
potential needed for action potential firing in a neuron. Our
study provides quantitative data in support of the general
belief that GIRK activation inhibits the excitability of a
neuron, and thus extends the results of earlier investigators
who have found hippocampal spike train inhibition by GIRK
FIG. 4. GIRK activation inhibits action potential firing. (a) Bars
indicate the application of 50 mM baclofen to a 13 d-cultured neuron
(3 d after coinfection with AdGIRK112), and of 5 mM ACh to an atrial
cell. A 15.8 sec current pulse of 160 pA was injected into the neuron
to cause firing; the myocyte was firing spontaneously. Resting EM were
270 mV (neuron) and 266 mV (myocyte). (b) EM responses of
AdGIRK112-coinfected neurons to 0.6 sec current pulses in the
presence (Right) and absence (Left) of 30 mM 5-HT (Upper) and 50 mM
baclofen (Lower); steps of 20 pA (Upper, from 220 pA) and 16 pA
(Lower, from 0 pA). Note that the 60 and 96 pA pulses cause action
potential firing in the absence but not in the presence of 5-HT and
baclofen, respectively (thick lines). (Inset) Firing frequencies calcu-
lated from action potential intervals of the top cell in the presence (n)
and absence (h) of 5-HT. Solid lines show linear fits; x axis intercepts
indicate ITh.
FIG. 5. Simulations of the effects of gGIRK on cell membrane
properties. (Upper Left) A simplified equivalent circuit incorporating
only GIRK and leakage conductances. The membrane capacitance
(Cm) is 50 pF. The leakage conductance (gleak, 55 pSypF) is linear with
a reversal potential of 212 mV (Eleak); gGIRK is as described in the text.
(Upper Right) Current–voltage relation for the simulated gGIRK. The
resting potential (260 mV in the absence of GIRK activation) is
simulated by an applied current of 2132 pA in both panels. (Lower)
Voltage changes in response to current injections (starting at 20 pA,
20 pA steps) with (Right) and without gGIRK (Left).
7074 Physiology: Ehrengruber et al. Proc. Natl. Acad. Sci. USA 94 (1997)
activation (e.g., refs. 5, 6, 40, and 41). Our data may explain the
recent observation that mice lacking GIRK2 and most of
GIRK1 are more seizure-prone than normal mice (42). It
remains to be determined whether adenovirus-mediated
GIRK overexpression could inhibit cellular hyperexcitability in
model systems of certain biological malfunctions, including
epilepsy and cardiac hypertrophy.
GIRKs occur postsynaptically in hippocampal CA1 neurons
(15, 26, 43, 44), where they are activated by 5-HT1A, GABAB,
adenosine A1, and opiate receptors (12–14, 41, 45, 46). The
principal serotonergic and opiate inputs are external to the
hippocampus. An understanding of these interactions will be
necessary for the study of synaptic function and plasticity in the
hippocampus.
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